medigraphic.com

2013, Number 2

<< Back Next >>

Rev Med Inst Mex Seguro Soc 2013; 51 (2)

Calciphylaxis, renal failure and gout. A patient with hyperuricemia as a risk factor for death

Martínez-Martínez MU, Román-Acosta S, Álvarez-Reyes JM, Oros-Ovalle C, Abud-Mendoza C

Language: Spanish
References: 14
Page: 218-221
PDF size: 101.98 Kb.


ABSTRACT

Background: gout is an inflammatory arthritis that frequently is associated to obesity, alcohol consumption, hypertension and hypertriglyceridemia. The calciphylaxis is characterized by metastatic calcifi cation to small and medium vessels. Both are associated independently with high mortality. When hyperuricemia and the calciphylaxis are present, the death risk is 80 %.
Clinical case: a 51 year old man presented with clinical history of alcoholism and systemic arterial hypertension, which developed limb ulcers, edema and uremic syndrome. Three week later, the patient died as consequences of sepsis by Staphylococcus aureus. We emphasize the diagnosis approach of calciphylaxis, metabolic syndrome and comorbidities, cardiovascular and renal failure risk factors.
Conclusions: the hyperuricemia is included in the metabolic syndrome, as the result of genetic and behavioral factors. It is recognized as a cardiovascular risk for this reason we must considered it in the clinical practice guidelines for the prevention and treatment of diseases with high mortality.


REFERENCES

  1. Neogi T. Clinical practice. Gout. N Engl J Med. 2011;364(5):443-52.

  2. Edwards NL. The role of hyperuricemia in vascular disorders. Curr Opin Rheumatol. 2009;21(2):132-7.

  3. Ng AT, Peng DH. Calciphylaxis. Dermatol Ther. 2011;24(2):256-62.

  4. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res. 2010;62(2):170-80.

  5. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J Nephrol. 2011; 24(2):142-8.

  6. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 31-2001. A 70-year-old woman with end-stage renal disease and cutaneous ulcers. N Engl J Med. 2001;345(15):1119-24.

  7. Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343(12):864-9.

  8. Sallah S, Abdallah JM, Gagnon GA. Recurrent warfarin- induced skin necrosis in kindreds with protein S defi ciency. Haemostasis. 1998;28(1):25-30.

  9. Verdalles-Guzmán U, de la Cueva P, Verde E, García-de Vinuesa S, Goicoechea M, Mosse A, et al. [Calciphylaxis: fatal complication of cardiometabolic syndrome in patients with end stage kidney disease]. Nefrologia. 2008;28(1):32-6.

  10. Polaina-Rusillo M, Sánchez-Martos MD, Biechy- Baldan MM, Liebana-Cañada A. The calciphylaxis. Semin Fund Esp Reumatol. 2009;10:124-27.

  11. Pérez-Ruiz F, Dalbeth N, Urresola A, De Miguel E, Schlesinger N. Imaging of gout: fi ndings and utility. Arthritis Res Ther. 2009;11(3):232. Texto libre en http://www.ncbi.nlm.nih.gov/pmc/articles/ PMC2714107/

  12. Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR. Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery. 2009;146(6):1028-34.

  13. Li JZ, Huen W. Images in clinical medicine. Calciphylaxis with arterial calcifi cation. N Engl J Med. 2007;357(13):1326. Texto libre en http://www. nejm.org/doi/full/10.1056/NEJMicm060859

  14. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med. 2002;69(8):594,597,600-2 passim. Texto libre en http://www.ccjm.org/content/69/8/594.long




2020     |     www.medigraphic.com